Multiple chamber ex vivo adjustable-release final dosage form
    7.
    发明申请
    Multiple chamber ex vivo adjustable-release final dosage form 审中-公开
    多室离体可调释最终剂型

    公开(公告)号:US20100069887A1

    公开(公告)日:2010-03-18

    申请号:US12387324

    申请日:2009-04-29

    IPC分类号: A61M37/00

    摘要: Described embodiments include a final dosage form, an article of manufacture, and method. A described final dosage form includes a dosage portion having a chamber carrying a medicament. The dosage portion also has a release element in a first medicament-release state wherein the medicament has a first bioavailability to the animal. The release element is modifiable ex vivo to a second medicament-release state by an exposure to a stimulus, wherein the medicament has a second bioavailability to the animal. The final dosage form includes another dosage portion having another chamber carrying another medicament. The another dosage portion also has another release element in another first medicament-release state wherein the another medicament has another first bioavailability to the animal. The another release element is modifiable ex vivo to another second medicament-release state by an exposure to another stimulus, wherein the another medicament has another second bioavailability to the animal.

    摘要翻译: 描述的实施方案包括最终剂型,制品和方法。 所描述的最终剂型包括具有携带药物的室的剂量部分。 剂量部分还具有处于第一药物释放状态的释放元件,其中药物对动物具有第一生物利用度。 释放元件通过暴露于刺激物离体修饰成第二药物释放状态,其中药物对动物具有第二生物利用度。 最终剂型包括另一个剂量部分,其具有另一个容纳另一种药物的腔室。 另一剂量部分还具有另一第一药物释放状态中的另一释放元件,其中另一种药物对动物具有另一种第一生物利用度。 另一种释放元件可通过暴露于另一种刺激物离体修饰成另一种第二药物释放状态,其中另一种药物对动物具有另一种第二生物利用度。

    Ex vivo modifiable medicament release-sites final dosage form
    8.
    发明申请
    Ex vivo modifiable medicament release-sites final dosage form 审中-公开
    体外可修改的药物释放位点最终剂型

    公开(公告)号:US20100069821A1

    公开(公告)日:2010-03-18

    申请号:US12387323

    申请日:2009-04-29

    IPC分类号: A61N1/30 A61N5/00 A61N7/00

    CPC分类号: A61K9/0009 A61K9/127

    摘要: Described embodiments include a final dosage form, an article of manufacture, and method. A described final dosage form includes a dosage portion having a medicament, and a site and the medicament in a first association. In the first association, the medicament has a first bioavailability. The first association of the site and the medicament is modifiable ex vivo to a second association an exposure to a stimulus, wherein the medicament has a second bioavailability. The final dosage form includes another dosage portion having another medicament, and another site and the another medicament in another first association. In the another first association, the another medicament has another first bioavailability. The another first association is modifiable ex vivo to another second association of the another site and the another medicament by an exposure to another stimulus, wherein the another medicament has another second bioavailability.

    摘要翻译: 描述的实施方案包括最终剂型,制品和方法。 所描述的最终剂型包括具有药物的剂量部分和第一结合中的部位和药物。 在第一关联中,药物具有第一生物利用度。 所述部位和所述药物的第一结合物可以离体修饰为暴露于刺激物的第二缔合,其中所述药物具有第二生物利用度。 最终剂型包括具有另一种药物的另一剂量部分,另一个部位和另一个第一关联的另一药物。 在另一个第一关联中,另一种药物具有另一种第一生物利用度。 另一个第一关联可以通过暴露于另一种刺激离体修饰为另一个位点与另一种药物的另一第二缔合,其中另一种药物具有另一种第二生物利用度。

    Ex vivo modifiable multiple medicament final dosage form
    9.
    发明申请
    Ex vivo modifiable multiple medicament final dosage form 失效
    体外可修改的多种药物最终剂型

    公开(公告)号:US20100068277A1

    公开(公告)日:2010-03-18

    申请号:US12387325

    申请日:2009-04-29

    IPC分类号: A61K9/14

    摘要: Described embodiments include a final dosage form for administering a medicament to an animal, an article of manufacture, and method. A described final dosage form includes a dosage portion having a medicament and a release element in a first medicament-release state. The medicament has a first bioavailability to the animal. The release element is modifiable ex vivo to a second medicament-release state by an exposure to a stimulus, wherein the medicament has a second bioavailability to the animal. The final dosage form includes another dosage portion having another medicament and another release element in another first medicament-release state. In the another first medicament-release state, the another medicament has another first bioavailability to the animal. The another release element is modifiable ex vivo to another second medicament-release state by an exposure to another stimulus, wherein the another medicament has another second bioavailability to the animal.

    摘要翻译: 描述的实施方案包括用于向动物施用药物的最终剂型,制品和方法。 描述的最终剂型包括具有药物和处于第一药物释放状态的释放元件的剂量部分。 药物对动物具有第一生物利用度。 释放元件通过暴露于刺激物离体修饰成第二药物释放状态,其中药物对动物具有第二生物利用度。 最终剂型包括具有另一药物的另一剂量部分和处于另一第一药物释放状态的另一释放元件。 在另一第一药物释放状态中,另一种药物对动物具有另一种第一生物利用度。 另一种释放元件可通过暴露于另一种刺激物离体修饰成另一种第二药物释放状态,其中另一种药物对动物具有另一种第二生物利用度。

    Personalizable dosage form
    10.
    发明申请
    Personalizable dosage form 审中-公开
    个性化剂型

    公开(公告)号:US20100068275A1

    公开(公告)日:2010-03-18

    申请号:US12284014

    申请日:2008-09-16

    IPC分类号: A61K9/14

    CPC分类号: A61K9/0009 A61K9/0068

    摘要: Provided embodiments include a final dosage form, an article of manufacture, and a method. A method of fulfilling a request specifying a dose of a medicament for an individual animal includes choosing pursuant to the request an instance of a final dosage form that includes the medicament. The method also includes selecting a stimulus effective to change a medicament-release state of a release element of the final dosage form. The method further includes initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus. The method further includes the release element configured in a first medicament-release state and changeable to a second medicament-release state upon an ex vivo exposure to a stimulus.

    摘要翻译: 所提供的实施方案包括最终剂型,制品和方法。 满足指定用于个体动物的药物剂量的请求的方法包括根据请求选择包括药物的最终剂型的实例。 该方法还包括选择有效改变最终剂型释放元件的药物释放状态的刺激物。 该方法还包括将所选择的最终剂型实例的释放元件离体暴露于所选择的刺激物。 该方法还包括在第一药物释放状态下配置的释放元件,并且在离体刺激刺激后可以变化到第二药物释放状态。